Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck KgaA Licenses Genome-Editing Technology to Two Companies

10/12/2020 | 09:10am EST

By Cecilia Butini

Merck KgaA said Monday that it has signed agreements with Canadian cell therapy firm PanCELLa Inc. and with U.S.-based biotechnology company Takara Bio USA, Inc. to license them its CRISPR genome-editing technology.

The German health-care company said licensing of the technology--which allows for the cutting of portions of DNA in order to make changes--has the goal of accelerating drug discovery research in order to develop new therapies.

PanCELLa will use Merck's CRISPR patent in the development of therapeutics with genetically modified cell lines, the company said.

Under the agreement, Takara Bio will use Merck's CRISPR integration and vector technologies for the development of its own vector products and cell engineering services, Merck said. In molecular biology, vectors are used to carry genetic material into cells.

Merck didn't disclose payment details related to the licensing agreements.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

10-12-20 0910ET

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA 1.52% 133.4 Delayed Quote.26.63%
TAKARA & COMPANY LTD. -0.60% 1990 End-of-day quote.14.90%
TAKARA BIO INC. 0.99% 2949 End-of-day quote.43.36%
TAKARA HOLDINGS INC. 0.67% 1209 End-of-day quote.20.30%
All news about MERCK KGAA
11/26MERCK : Partners With Siemens on New Plant
DJ
11/24Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/24MERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
EQ
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
AQ
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
AQ
11/17MERCK KGAA : UBS reiterates its Neutral rating
MD
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
MD
11/16MERCK KGAA : JP Morgan remains Neutral
MD
11/13MERCK KGAA : Deutsche Bank keeps its Buy rating
MD
More news
Financials
Sales 2020 17 381 M 20 791 M 20 791 M
Net income 2020 2 013 M 2 408 M 2 408 M
Net Debt 2020 11 224 M 13 426 M 13 426 M
P/E ratio 2020 28,6x
Yield 2020 1,06%
Capitalization 57 999 M 69 344 M 69 379 M
EV / Sales 2020 3,98x
EV / Sales 2021 3,70x
Nbr of Employees 58 077
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,37 €
Last Close Price 133,40 €
Spread / Highest target 26,7%
Spread / Average Target 1,48%
Spread / Lowest Target -24,3%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA26.63%69 344
INDIVIOR155.77%975
KNIGHT THERAPEUTICS INC.-27.18%554
MAYNE PHARMA GROUP LIMITED-17.24%441
CORMEDIX INC.23.08%288
ISOFOL MEDICAL AB (PUBL)-18.32%170